Collegium Pharmaceutical (NASDAQ:COLL) Sets New 12-Month Low – Should You Sell?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) reached a new 52-week low on Tuesday. The stock traded as low as $21.62 and last traded at $21.6960, with a volume of 250552 shares trading hands. The stock had previously closed at $22.63.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on COLL. Wall Street Zen downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings cut Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, September 4th. Needham & Company LLC reduced their price objective on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Oppenheimer assumed coverage on Collegium Pharmaceutical in a report on Wednesday, September 23rd. They set an “outperform” rating and a $50.00 price objective on the stock. Finally, Piper Sandler restated a “neutral” rating and set a $43.00 price objective (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 7th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $48.71.

Collegium Pharmaceutical Stock Down 3.5%

The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. The business has a 50-day simple moving average of $27.59 and a two-hundred day simple moving average of $32.04. The stock has a market capitalization of $710.95 million, a P/E ratio of 17.55, a PEG ratio of 0.73 and a beta of 0.72.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The company had revenue of $199.88 million during the quarter, compared to analysts’ expectations of $199.62 million. During the same period last year, the business earned $1.68 earnings per share. The business’s revenue was up 6.3% on a year-over-year basis. Equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.19 earnings per share for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds have recently modified their holdings of the company. WINTON GROUP Ltd bought a new position in Collegium Pharmaceutical in the 2nd quarter valued at $536,000. Squarepoint Ops LLC increased its position in Collegium Pharmaceutical by 124.8% in the 2nd quarter. Squarepoint Ops LLC now owns 47,897 shares of the specialty pharmaceutical company’s stock valued at $1,734,000 after acquiring an additional 26,589 shares in the last quarter. Corient Private Wealth LP increased its holdings in shares of Collegium Pharmaceutical by 60.5% in the second quarter. Corient Private Wealth LP now owns 71,870 shares of the specialty pharmaceutical company’s stock valued at $2,603,000 after purchasing an additional 27,097 shares in the last quarter. Amundi raised its position in shares of Collegium Pharmaceutical by 188.0% during the second quarter. Amundi now owns 23,492 shares of the specialty pharmaceutical company’s stock worth $850,000 after acquiring an additional 15,336 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Collegium Pharmaceutical during the second quarter valued at $295,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company’s portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs.

Collegium’s pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain.